Hoegen, P.
Zhang, K. S.
Tonndorf-Martini, E.
Weykamp, F.
Regnery, S.
Naumann, P.
Lang, K.
Ristau, J.
Körber, S. A.
Dreher, C.
Buchele, C.
Rippke, C.
Renkamp, C. K.
Paul, K. M.
König, L.
Büsch, C.
Krisam, J.
Sedlaczek, O.
Schlemmer, H.-P.
Niyazi, M.
Corradini, S.
Debus, J.
Klüter, S.
Hörner-Rieber, J.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 28 January 2022
Accepted: 14 March 2022
First Online: 27 March 2022
Declarations
:
: The final study protocol was approved by the ethics committee of the Medical Faculty of Heidelberg University (S-002/2021). In the clinical study, no ionizing radiation in humans for the purpose of medical research will be used, since all treatments within this protocol are clinically indicated and performed within the medical responsibility of the participating centers and only clinically established therapies and diagnostics are used. The study was submitted to the DEGRO expert committee for advice and the committee classified the protocol as medical science (“Heilkunde”). An application to the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz, BfS) is therefore not required. This study complies with the Helsinki Declaration and its recent German version, the Medical Association code of conduct, the principles of Good Clinical Practice (GCP) and the Federal Data Protection Act. The trial will be carried out in keeping with local legal and regulatory requirements. Each patient must provide written informed consent for participation in the study and for publication before enrollment.
: Not applicable.
: J. H.-R. and S. K. received speaker fees and travel reimbursement from ViewRay Inc. J. H.-R. received travel reimbursement from IntraOP Medical and Elekta Instrument AB and a grant from IntraOP Medical outside the submitted work. M. N. received speaker fees and honoraria from Brainlab AG and Novocure. J.D. received grants from CRI—The Clinical Research Institute GmbH, Accuray International Sàrl, View Ray Inc., Accuray Incorporated, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A.A., Merck Serono GmbH and IntraOP Medical outside the submitted work.